Bank Julius Baer & Co
VRDN icon

Bank Julius Baer & Co’s Viridian Therapeutics VRDN Stock Holding History

Bank Julius Baer & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-83
Closed -$1K – 856
2020
Q3 		$1K Hold
83
– – ﹤0.01% 731
2020
Q2 		$1K Sell
83
-66
-44% -$749 ﹤0.01% 681
2020
Q1 		$1K Buy
+149
New +$1.73K ﹤0.01% 632

Other funds holding VRDN

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bank Julius Baer & Co's VRDN Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of Viridian Therapeutics (VRDN) in Q4 2020, closing a stake of 83 shares — an estimated $1K sold.

Bank Julius Baer & Co first reported a position in VRDN in Q1 2020 and held it in 3 quarters. The position peaked at $1K in Q3 2020. 22 funds tracked by Wall St. Rank hold VRDN as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining Viridian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 83 Viridian Therapeutics shares in Q4 2020, an estimated $1K.
  • Bank Julius Baer & Co first reported a position in Viridian Therapeutics in Q1 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Viridian Therapeutics position peaked at $1K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.